For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
9
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      497
      similar
       All similar

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nasal vestibule squamous cell carcinoma (SCC) is a rare malignancy with limited treatment options. This case report presents an 83-year-old female with SCC of the nasal vestibule who was ineligible for surgery or radiotherapy due to various factors. The patient was successfully treated with cemiplimab, a systemic anti-PD-1 antibody, resulting in a remarkable tumor reduction without any observed side effects. This is the first reported case of nasal vestibule SCC treated with cemiplimab, highlighting its potential as a promising therapeutic option.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

          Victor Moreno, Michael Migden, Danny Rischin … (2018)
          No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.
          Article 0 comments Cited 517 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis

            Zhenjie Wu, Qi Chen, Le Qu … (2022)
            Article 0 comments Cited 36 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA.

              Mads V Filtenborg, Jacob K Lilja-Fischer, Maja B Sharma … (2022)
              Cancer of the nasal vestibule is a rare type of malignancy dominated by squamous cell carcinoma (SCC), and with poor survival. The treatment is either radiotherapy, surgery or a combination of both. Previous studies have shown a 5-year disease-specific survival of 74% and overall survival (OS) of 50%.Our objective was to describe the consecutive cohort of patients diagnosed with SCC of the nasal vestibule in Denmark from 2008 until 2018 and evaluate prognostic factors and treatment outcome using locoregional failure (LRF), disease-specific mortality (DSM), and OS as endpoints.
              Article 0 comments Cited 4 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Case Rep Oncol
                Journal ID (iso-abbrev): Case Rep Oncol
                Journal ID (hwp): CRO
                Journal ID (publisher-id): CRO
                Title: Case Reports in Oncology
                Publisher: S. Karger AG (Basel, Switzerland )
                ISSN (Electronic): 1662-6575
                Publication date (Electronic): 19 September 2023
                Publication date Collection: Jan-Dec 2023
                Publication date PMC-release: 19 September 2023
                Volume: 16
                Issue: 1
                Pages: 935-938
                Affiliations
                [a ]Oncolgy Unit, “Andrea Tortora” Hospital, ASL Salerno, Pagani, Italy
                [b ]Associazione O.R.A.-Oncology Research Assistance, Somma Vesuviana, Italy
                [c ]Dermatology Unit, “Andrea Tortora” Hospital, ASL Salerno, Pagani, Italy
                [d ]Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, IRCCS Pascale, Naples, Italy
                Author notes
                Correspondence to: Giuseppe Di Lorenzo, direttoreuocpagani@ 123456gmail.com
                Article
                Publisher ID: 531843
                DOI: 10.1159/000531843
                PMC ID: 10601738
                PubMed ID: 37900804
                SO-VID: d921a328-432e-4d46-8d91-6e7ffdc2d5fe
                Copyright © © 2023 The Author(s). Published by S. Karger AG, Basel
                License:

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                Date received : 7 June 2023
                Date accepted : 30 June 2023
                Date: 2023
                Page count
                Figures: 1, References: 8, Pages: 4
                Funding
                This research was partially supported by funding from the EUBEA Agency, Naples, Italy, which provided financial support for the publication fees of this article.
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: cemiplimab,squamous cell carcinoma,immunotherapy,skin cancer
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: cemiplimab, squamous cell carcinoma, immunotherapy, skin cancer

                Comments

                Comment on this article

                scite_

                Similar content497

                See all similar

                Most referenced authors156

                See all reference authors